GlassScriptPhysician profile
Susan Kemp
NPI 1972586527
$3,130.38
in general payments reported to CMS, 2019-2025
30 companies · $288 in 2025
The $288 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,342 · 2020: $348 · 2021: $198 · 2022: $503 · 2023: $170 · 2024: $282 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $739.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $671.54 | 2019-2025 | Ozempic, Rybelsus |
| Organogenesis INC. | $404.93 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $365.78 | 2019-2022 | |
| Abbvie INC. | $193.57 | 2021-2025 | |
| Smith+Nephew, INC. | $181.15 | 2021-2024 | Collagenase Santyl, Regranex |
| Melinta Therapeutics, LLC | $158.21 | 2019-2024 | Kimyrsa, Orbactiv, Rezzayo |
| Janssen Pharmaceuticals, INC | $133.54 | 2019 | |
| Ucb, INC. | $114.98 | 2019 | |
| Paratek Pharmaceuticals, INC. | $110.21 | 2020-2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $100.67 | 2019-2020 | |
| Glaxosmithkline, LLC. | $81.80 | 2019-2024 | Trelegy Ellipta |
| Mimedx Group, INC. | $67.73 | 2024-2025 | |
| Pfizer INC. | $63.65 | 2020-2021 | |
| Lilly USA, LLC | $60.55 | 2019-2025 | Zepbound, Mounjaro |
| Inari Medical, INC. | $56.23 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.31 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $45.97 | 2019 | |
| Sanofi-Aventis U.S. LLC | $42.32 | 2019 | |
| Astellas Pharma US INC | $35.41 | 2019 | |
| Kci USA, INC. | $30.05 | 2019 | |
| Integra Lifesciences Corporation | $28.14 | 2024 | Tcc-Ez |
| Urgo Medical North America, LLC | $26.53 | 2024 | Urgoclean Ag |
| Otsuka America Pharmaceutical, INC. | $22.98 | 2025 | Rexulti |
| Solventum Corporation | $16.50 | 2024 | Activ.A.C. |
| Alexion Pharmaceuticals, INC. | $15.41 | 2020 | |
| Tactile Systems Technology INC | $15.38 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.07 | 2019 | |
| Amgen INC. | $14.98 | 2019 | |
| Novartis Pharmaceuticals Corporation | $10.79 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Kemp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.